PLC Plc Systems,

- - PLC's Japanese Distributor Introduces CO2 TMR Heart Laser Technology At The ASCVS Annual Meeting - - FRANKLIN, Mass., June 5 /PRNewswire-FirstCall/ -- PLC Systems Inc. (AMEX:PLC), a leader in cardiac laser technologies, today reported that Professor Hans-Michael Klein from the Medical School of Duesseldorf University in Germany presented a paper entitled "Stem Cell Therapy in Cardiac Surgery" at the 14th Annual Meeting of the Asian Society for Cardiovascular Surgery (ASCVS) in Osaka, Japan. This lecture focused on the intramyocardial application of bone marrow derived stem cells in combination with CO2 TMR. Dr. Klein, a cardiac surgeon who has extensive experience with CO2 TMR and Stem Cell Therapy, provided a review of new innovative cardiac tissue regeneration research. The presentation included data on stem cell therapy alone, stem cells with coronary artery bypass graph (CABG) surgery, and stem cells combined with CO2 TMR. Dr. Klein's presentation concluded that stem cells combined with CO2 TMR provide an increased improvement in cardiac function in heart failure patients when compared to stem cells alone or stem cells with CABG. "Due to the growing number of heart failure patients not amenable to revascularization techniques such as CABG, the CO2 TMR and stem cell therapy has significant potential as an effective procedure for seriously ill coronary artery disease patients," said Professor Klein, Germany. "Our research has demonstrated that CO2 TMR can initiate an internal angiogenic response, which is critical when we are striving for tissue regeneration. At our institution we have performed more than 30 CO2 TMR plus stem cell procedures. We believe that when autologous bone marrow cells are injected into the patient's heart around the laser channel, the mediators released in response to the laser procedure attract the bone marrow cells, also known as the homing effect, which starts a cascade of events leading to an angiogenic and vasogenic response that can improve cardiac function in heart failure patients." In addition to the CO2 TMR and stem cell presentation, PLC's CO2 TMR Heart Laser technology was introduced at the ASCVS Annual Meeting. In May 2006, PLC announced that the Company's Japanese distributor received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market PLC Systems' first generation CO2 TMR Heart Laser System (HL1) in Japan. "The Asian Society for Cardiovascular Surgery Annual Meeting is a very important event for our technology," stated Mark R. Tauscher, president and CEO of PLC Systems. "We are very pleased to see Dr. Klein discussing his cutting edge research and experiences with the members of the Asian cardiac community. TMR plus stem cells could be the right solution for cardiac surgeons that are treating heart patients who have limited revascularization therapy choices." About PLC Systems Inc. PLC Systems is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. Coronary artery disease is expected to increase as the worldwide population continues to age. Working with leading researchers and premier heart centers around the world, PLC developed the CO2 Heart Laser, which is the world's first TMR angina relief device approved by both the Japanese MHLW and the U.S. Food and Drug Administration. Additional company information can be found at http://www.plcmed.com/. This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including our Japanese distributor may decide not to pursue or continue Japanese sales and marketing activities for the Heart Laser; our Japanese distributor may be unsuccessful in selling these products in Japan, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, we may be unable to convince health care professionals and third party payers of the medical and economic benefits of the CO2 Heart Lasers, and there can be no assurance that all payers will reimburse health care providers who perform TMR procedures or that reimbursement, if provided, will be adequate, and additional risk factors described in our Report on Form 10-K for the year ended December 31, 2005, and our other SEC reports. PLC Systems, PLC Medical Systems, PLC and CO2 Heart Laser are trademarks of PLC Systems Inc. Contact: John Jordan Director of Investor Relations 508-541-8800, ext. 145 DATASOURCE: PLC Systems Inc. CONTACT: John Jordan, Director of Investor Relations at PLC Systems, +1-508-541-8800, ext. 145 Web site: http://www.plcmed.com/

Copyright